Antigenicity and Immunogenicity of Plasmodium vivax Merozoite Surface Protein-3

Antigenicity and Immunogenicity of Plasmodium vivax Merozoite Surface Protein-3

Author Bitencourt, Amanda R. Google Scholar
Vicentin, Elaine C. Google Scholar
Jimenez, Maria C. Google Scholar
Ricci, Ricardo Google Scholar
Leite, Juliana A. Google Scholar
Costa, Fabio Trindade Maranhão Autor UNIFESP Google Scholar
Ferreira, Luis C. Google Scholar
Russell, Bruce Google Scholar
Nosten, Francois Google Scholar
Renia, Laurent Google Scholar
Galinski, Mary R. Google Scholar
Barnwell, John W. Google Scholar
Rodrigues, Mauricio Martins Autor UNIFESP Google Scholar
Soares, Irene S. Google Scholar
Institution Universidade de São Paulo (USP)
Universidade Estadual de Campinas (UNICAMP)
Natl Univ Singapore
Agcy Sci Technol & Res
Churchill Hosp
Mahidol Oxford Univ Trop Med Res Programme
Emory Univ
Ctr Dis Control & Prevent
Universidade Federal de São Paulo (UNIFESP)
Abstract A recent clinical trial in African children demonstrated the potential utility of merozoite surface protein (MSP)-3 as a vaccine against Plasmodium falciparum malaria. the present study evaluated the use of Plasmodium vivax MSP-3 (PvMSP-3) as a target antigen in vaccine formulations against malaria caused by P. vivax. Recombinant proteins representing MSP-3 alpha and MSP-3 beta of P. vivax were expressed as soluble histidine-tagged bacterial fusions. Antigenicity during natural infection was evaluated by detecting specific antibodies using sera from individuals living in endemic areas of Brazil. A large proportion of infected individuals presented IgG antibodies to PvMSP-3 alpha (68.2%) and at least 1 recombinant protein representing PvMSP-3 beta (79.1%). in spite of the large responder frequency, reactivity to both antigens was significantly lower than was observed for the immunodominant epitope present on the 19-kDa C-terminal region of PvMSP-1. Immunogenicity of the recombinant proteins was studied in mice in the absence or presence of different adjuvant formulations. PvMSP-3 beta, but not PvMSP-3 alpha, induced a TLR4-independent humoral immune response in the absence of any adjuvant formulation. the immunogenicity of the recombinant antigens were also tested in formulations containing different adjuvants (Alum, Salmonella enterica flagellin, CpG, Quil A, TiterMax (R) and incomplete Freunds adjuvant) and combinations of two adjuvants (Alum plus flagellin, and CpG plus flagellin). Recombinant PvMSP-3 alpha and PvMSP-3 beta elicited higher antibody titers capable of recognizing P. vivax-infected erythrocytes harvested from malaria patients. Our results confirm that P. vivax MSP-3 antigens are immunogenic during natural infection, and the corresponding recombinant proteins may be useful in elucidating their vaccine potential.
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
US National Institutes of Health, National Institute for Allergy and Infectious Diseases
Horizontal Programme on Infectious Diseases under the Agency for Science, Technology and Research (A*STAR, Singapore)
Wellcome Trust of Great Britain, as part of the Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol University
Grant number FAPESP: 2010/09893-0
US National Institutes of Health, National Institute for Allergy and Infectious Diseases: 1R01AI24710
Date 2013-02-14
Published in Plos One. San Francisco: Public Library Science, v. 8, n. 2, 10 p., 2013.
ISSN 1932-6203 (Sherpa/Romeo, impact factor)
Publisher Public Library Science
Extent 10
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000315602700037

Show full item record


Name: WOS000315602700037.pdf
Size: 1.044Mb
Format: PDF
Open file

This item appears in the following Collection(s)




My Account